By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > BCR-ABL tyrosine kinase inhibitors > Iclusig > Iclusig Dosage
BCR-ABL tyrosine kinase inhibitors
https://themeditary.com/dosage-information/iclusig-dosage-624.html

Iclusig Dosage

Drug Detail:Iclusig (Ponatinib [ poe-na-ti-nib ])

Generic Name: ponatinib hydrochloride 15mg

Dosage Form: tablet, film coated

Drug Class: BCR-ABL tyrosine kinase inhibitors Multikinase inhibitors VEGF/VEGFR inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Recommended Dosage

CP-CML

The recommended starting dosage is 45 mg orally once daily with a reduction to 15 mg orally once daily upon achievement of ≤1% BCR-ABL1IS. Patients with loss of response can re-escalate the dose of Iclusig to a previously tolerated dosage of 30 mg or 45 mg orally once daily. Continue Iclusig until loss of response at the re-escalated dose or unacceptable toxicity.

Consider discontinuing Iclusig if hematologic response has not occurred by 3 months.

AP-CML, BP-CML, and Ph+ ALL

The optimal dose of Iclusig has not been identified.

The recommended starting dosage of Iclusig is 45 mg orally once daily. Consider reducing the dose of Iclusig for patients with accelerated phase (AP) CML who have achieved a major cytogenetic response. Continue Iclusig until loss of response or unacceptable toxicity.

Consider discontinuing Iclusig if response has not occurred by 3 months.

Administration

Advise patients of the following:

  • Iclusig may be taken with or without food.
  • Swallow tablets whole. Do not crush, break, cut or chew tablets.
  • If a dose is missed, take the next dose at the regularly scheduled time the next day.

Dosage Modifications for Adverse Reactions

Recommended dosage modifications of Iclusig for adverse reactions are provided in Table 1 and recommended dose reductions of Iclusig for adverse reactions are presented in Table 2.

Table 1: Recommended Dosage Modifications for Iclusig for Adverse Reactions
Adverse Reaction Severity Iclusig Dosage Modifications
Based on CTCAE v5.0: Grade 1 mild, Grade 2 moderate, Grade 3 severe, Grade 4 life-threatening
ULN = Upper Limit of Normal for the lab; AOE = Arterial Occlusive Event; VTE = Venous Thromboembolic Event; ANC = absolute neutrophil count
AOE: cardiovascular or cerebrovascular
[see Warnings and Precautions (5.1)]
Grade 1 Interrupt Iclusig until resolved, then resume at same dose.
Grade 2 Interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
Discontinue Iclusig if recurrence.
Grade 3 or 4 Discontinue Iclusig.
AOE: peripheral vascular and other
or
VTE
[see Warnings and Precautions (5.1, 5.2)]
Grade 1 Interrupt Iclusig until resolved, then resume at same dose.
Grade 2 Interrupt Iclusig until Grade 0 or 1, then resume at same dose.
If recurrence, interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
Grade 3 Interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
Discontinue Iclusig if recurrence.
Grade 4 Discontinue Iclusig.
Heart Failure
[see Warnings and Precautions (5.3)]
Grade 2 or 3 Interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
Discontinue Iclusig if recurrence.
Grade 4 Discontinue Iclusig.
Hepatotoxicity
[see Warnings and Precautions (5.4)]
AST or ALT greater than 3 times ULN Interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
AST or ALT at least 3 times ULN concurrent with bilirubin greater than 2 times ULN and alkaline phosphatase less than 2 times ULN Discontinue Iclusig.
Pancreatitis and Elevated Lipase
[see Warnings and Precautions (5.6)]
Serum lipase greater than 1 to 1.5 times ULN Consider interrupting Iclusig until resolution, then resume at same dose.
Serum lipase greater than 1.5 to 2 times ULN, 2 to 5 times ULN and asymptomatic, or asymptomatic radiologic pancreatitis Interrupt Iclusig until Grade 0 or 1 (less than 1.5 times ULN), then resume at next lower dose.
Serum lipase greater than 2 to 5 times ULN and symptomatic, symptomatic Grade 3 pancreatitis, or serum lipase greater than 5 times ULN and asymptomatic Interrupt Iclusig until complete resolution of symptoms and after recovery of lipase elevation Grade 0 or 1, then resume at next lower dose.
Symptomatic pancreatitis and serum lipase greater than 5 times ULN Discontinue Iclusig.
Myelosuppression
[see Warnings and Precautions (5.13)]
ANC less than 1 × 109/L
or
Platelets less than 50 × 109/L
Interrupt Iclusig until ANC at least 1.5 × 109/L and platelet at least 75 × 109/L, then resume at same dose.
If recurrence, interrupt Iclusig until resolution, then resume at next lower dose.
Other Non-hematologic Adverse Reactions
[see Warnings and Precautions (5.5, 5.8, 5.10, 5.11, 5.12)]
Grade 1 Interrupt Iclusig until resolved, then resume at same dose.
Grade 2 Interrupt Iclusig until Grade 0 or 1, then resume at same dose.
If recurrence, interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
Grade 3 or 4 Interrupt Iclusig until Grade 0 or 1, then resume at next lower dose.
Discontinue Iclusig if recurrence.
Table 2: Recommended Dose Reductions for Iclusig for Adverse Reactions
Dose Reduction Dosage for Patients with CP-CML Dosage for Patients with AP-CML, BP-CML, and Ph+ ALL
First 30 mg orally once daily 30 mg orally once daily
Second 15 mg orally once daily 15 mg orally once daily
Third 10 mg orally once daily Permanently discontinue Iclusig in patients unable to tolerate 15 mg orally once daily.
Subsequent Reduction Permanently discontinue Iclusig in patients unable to tolerate 10 mg orally once daily.

Dosage Modification for Coadministration of Strong CYP3A Inhibitors

Avoid coadministration of Iclusig with strong CYP3A inhibitors. If coadministration of a strong CYP3A inhibitor cannot be avoided, reduce the dosage of Iclusig as recommended in Table 3.

After the strong CYP3A inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the Iclusig dosage that was tolerated prior to initiating the strong CYP3A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

Table 3: Recommended Iclusig Dosage for Coadministration of Strong CYP3A Inhibitors
Current Iclusig Dosage Recommended Iclusig Dosage with a Strong CYP3A Inhibitor
45 mg orally once daily 30 mg orally once daily
30 mg orally once daily 15 mg orally once daily
15 mg orally once daily 10 mg orally once daily
10 mg orally once daily Avoid coadministration of Iclusig with a strong CYP3A inhibitor

Dosage for Patients with Hepatic Impairment

Reduce the starting dose of Iclusig from 45 mg orally once daily to 30 mg orally once daily in patients with pre-existing hepatic impairment (Child-Pugh A, B, or C) [see Use in Specific Populations (8.6)].

Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by